Viridian Therapeutics Stock Price History
VRDN Stock | USD 12.34 0.74 6.38% |
Below is the normalized historical share price chart for Viridian Therapeutics extending back to June 18, 2014. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Viridian Therapeutics stands at 12.34, as last reported on the 5th of June, with the highest price reaching 12.50 and the lowest price hitting 11.43 during the day.
If you're considering investing in Viridian Stock, it is important to understand the factors that can impact its price. Viridian Therapeutics owns Efficiency Ratio (i.e., Sharpe Ratio) of -0.23, which indicates the firm had a -0.23% return per unit of risk over the last 3 months. Viridian Therapeutics exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please validate Viridian Therapeutics' Variance of 11.22, coefficient of variation of (442.19), and Risk Adjusted Performance of (0.13) to confirm the risk estimate we provide.
At this time, Viridian Therapeutics' Stock Based Compensation is very stable compared to the past year. As of the 5th of June 2024, Stock Based Compensation To Revenue is likely to grow to 224.62, while Capital Stock is likely to drop about 122 M. . At this time, Viridian Therapeutics' Price To Sales Ratio is very stable compared to the past year. As of the 5th of June 2024, Price Book Value Ratio is likely to grow to 3.95, while Price Earnings Ratio is likely to drop (4.31). Viridian Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 18th of June 2014 | 200 Day MA 16.8611 | 50 Day MA 14.6876 | Beta 1.166 |
Viridian |
Sharpe Ratio = -0.231
Best Portfolio | Best Equity | |||
Good Returns | ||||
Average Returns | ||||
Small Returns | ||||
Cash | Small Risk | Average Risk | High Risk | Huge Risk |
Negative Returns | VRDN |
Estimated Market Risk
3.27 actual daily | 28 72% of assets are more volatile |
Expected Return
-0.76 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
-0.23 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Viridian Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Viridian Therapeutics by adding Viridian Therapeutics to a well-diversified portfolio.
Price Book 4.2404 | Enterprise Value Ebitda (3.18) | Price Sales 3.2 K | Shares Float 47.8 M | Wall Street Target Price 36.5 |
Viridian Therapeutics Stock Price History Chart
There are several ways to analyze Viridian Stock price data. The simplest method is using a basic Viridian candlestick price chart, which shows Viridian Therapeutics price history and the buying and selling dynamics of a specified period. Many traders also use subjective judgment to their trading calls, avoiding the need to trade based on technical analysis.
Highest Price | March 11, 2024 | 19.69 |
Lowest Price | June 4, 2024 | 11.6 |
Viridian Therapeutics June 5, 2024 Stock Price Synopsis
Various analyses of Viridian Therapeutics' daily price changes, such as its Balance Of Power or Price Action, are crucial when deciding whether to buy, hold, or sell Viridian Stock. It can be used to describe the percentage change in the price of Viridian Therapeutics from one trading day to the next and could be a valuable metric for traders and investors to gauge the volatility and momentum of Viridian Stock.Viridian Therapeutics Price Daily Balance Of Power | 0.69 | |
Viridian Therapeutics Accumulation Distribution | 93,328 | |
Viridian Therapeutics Price Rate Of Daily Change | 1.06 | |
Viridian Therapeutics Price Action Indicator | 0.75 |
Viridian Therapeutics June 5, 2024 Stock Price Analysis
Viridian Stock Price History Data
The price series of Viridian Therapeutics for the period between Thu, Mar 7, 2024 and Wed, Jun 5, 2024 has a statistical range of 8.29 with a coefficient of variation of 14.68. The daily prices for the period are distributed with arithmetic mean of 15.47. The median price for the last 90 days is 15.4. The company experienced 1:15 stock split on 13th of November 2020. Viridian Therapeutics paid out dividends to its shareholders on 2020-11-13.Open | High | Low | Close | Volume | ||
06/05/2024 | 11.73 | 12.50 | 11.43 | 12.34 | 1,090,277 | |
06/04/2024 | 11.95 | 12.01 | 11.40 | 11.60 | 859,629 | |
06/03/2024 | 12.17 | 12.59 | 11.93 | 12.00 | 1,289,331 | |
05/31/2024 | 12.07 | 12.24 | 11.87 | 11.95 | 879,768 | |
05/30/2024 | 12.19 | 12.32 | 11.83 | 11.94 | 773,485 | |
05/29/2024 | 11.90 | 12.20 | 11.84 | 11.98 | 625,309 | |
05/28/2024 | 12.30 | 12.58 | 11.91 | 12.19 | 1,048,647 | |
05/24/2024 | 12.25 | 12.62 | 11.99 | 12.11 | 908,812 | |
05/23/2024 | 12.73 | 12.73 | 11.78 | 12.16 | 1,377,183 | |
05/22/2024 | 12.95 | 13.24 | 12.66 | 12.70 | 665,816 | |
05/21/2024 | 13.50 | 13.55 | 12.73 | 12.88 | 801,612 | |
05/20/2024 | 13.49 | 13.68 | 13.01 | 13.53 | 1,310,446 | |
05/17/2024 | 14.60 | 14.76 | 13.39 | 13.45 | 1,106,910 | |
05/16/2024 | 14.39 | 14.79 | 13.94 | 14.63 | 807,831 | |
05/15/2024 | 15.12 | 15.44 | 14.20 | 14.27 | 719,140 | |
05/14/2024 | 14.65 | 15.05 | 14.35 | 14.67 | 640,880 | |
05/13/2024 | 14.13 | 14.71 | 13.93 | 14.34 | 630,499 | |
05/10/2024 | 14.05 | 14.06 | 13.34 | 13.90 | 858,169 | |
05/09/2024 | 14.18 | 14.34 | 13.50 | 13.91 | 1,729,827 | |
05/08/2024 | 15.51 | 15.71 | 14.41 | 14.90 | 1,013,672 | |
05/07/2024 | 15.74 | 15.76 | 14.91 | 15.14 | 643,741 | |
05/06/2024 | 15.49 | 15.70 | 15.18 | 15.59 | 568,997 | |
05/03/2024 | 15.08 | 15.50 | 15.01 | 15.40 | 757,897 | |
05/02/2024 | 14.05 | 14.63 | 13.95 | 14.58 | 854,629 | |
05/01/2024 | 13.31 | 14.40 | 13.31 | 13.81 | 1,018,259 | |
04/30/2024 | 13.32 | 13.79 | 13.20 | 13.26 | 898,245 | |
04/29/2024 | 13.04 | 13.63 | 12.58 | 13.60 | 1,074,004 | |
04/26/2024 | 12.74 | 13.06 | 12.43 | 12.88 | 538,173 | |
04/25/2024 | 12.92 | 12.96 | 12.20 | 12.70 | 958,729 | |
04/24/2024 | 14.38 | 14.68 | 12.99 | 13.03 | 771,185 | |
04/23/2024 | 14.39 | 15.01 | 14.23 | 14.25 | 538,426 | |
04/22/2024 | 14.74 | 14.74 | 14.00 | 14.30 | 812,430 | |
04/19/2024 | 15.09 | 15.52 | 14.40 | 14.60 | 1,489,689 | |
04/18/2024 | 15.07 | 15.75 | 14.93 | 15.16 | 580,684 | |
04/17/2024 | 15.20 | 15.26 | 14.85 | 15.08 | 661,453 | |
04/16/2024 | 15.49 | 15.54 | 15.02 | 15.09 | 679,991 | |
04/15/2024 | 15.81 | 15.95 | 15.20 | 15.64 | 881,394 | |
04/12/2024 | 16.27 | 16.32 | 15.67 | 15.89 | 773,632 | |
04/11/2024 | 16.36 | 16.47 | 15.95 | 16.21 | 587,299 | |
04/10/2024 | 16.08 | 16.38 | 15.53 | 16.11 | 955,428 | |
04/09/2024 | 17.02 | 17.33 | 16.53 | 16.85 | 553,388 | |
04/08/2024 | 16.42 | 17.10 | 16.28 | 16.90 | 530,435 | |
04/05/2024 | 16.10 | 16.62 | 15.71 | 16.32 | 493,963 | |
04/04/2024 | 16.41 | 16.85 | 16.11 | 16.32 | 1,008,403 | |
04/03/2024 | 16.48 | 16.80 | 16.17 | 16.26 | 586,935 | |
04/02/2024 | 16.90 | 16.90 | 16.42 | 16.69 | 913,384 | |
04/01/2024 | 17.69 | 17.69 | 16.88 | 17.26 | 608,789 | |
03/28/2024 | 17.67 | 17.93 | 17.21 | 17.51 | 1,010,508 | |
03/27/2024 | 17.56 | 18.02 | 17.14 | 17.51 | 707,738 | |
03/26/2024 | 17.86 | 17.87 | 17.25 | 17.37 | 621,252 | |
03/25/2024 | 17.99 | 18.33 | 17.30 | 17.55 | 921,860 | |
03/22/2024 | 18.69 | 18.94 | 17.85 | 18.01 | 849,852 | |
03/21/2024 | 18.30 | 19.07 | 17.92 | 18.78 | 1,407,893 | |
03/20/2024 | 17.29 | 18.16 | 17.23 | 18.10 | 1,077,131 | |
03/19/2024 | 17.31 | 18.01 | 17.18 | 17.21 | 1,131,556 | |
03/18/2024 | 16.95 | 17.62 | 16.16 | 17.34 | 1,536,114 | |
03/15/2024 | 17.14 | 17.73 | 16.90 | 17.09 | 3,851,767 | |
03/14/2024 | 17.58 | 17.76 | 16.80 | 17.25 | 977,782 | |
03/13/2024 | 17.61 | 18.01 | 17.26 | 17.81 | 778,016 | |
03/12/2024 | 19.46 | 19.65 | 17.55 | 17.60 | 895,705 | |
03/11/2024 | 19.29 | 20.23 | 19.20 | 19.69 | 1,071,492 |
About Viridian Therapeutics Stock history
Viridian Therapeutics investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Viridian is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Viridian Therapeutics will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Viridian Therapeutics stock prices may prove useful in developing a viable investing in Viridian Therapeutics
Last Reported | Projected for Next Year | ||
Common Stock Shares Outstanding | 44.8 M | 47 M | |
Net Loss | -116.9 M | -111 M |
Viridian Therapeutics Quarterly Net Working Capital |
|
Viridian Therapeutics Stock Technical Analysis
Viridian Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Did you try this?
Run Portfolio Analyzer Now
Portfolio AnalyzerPortfolio analysis module that provides access to portfolio diagnostics and optimization engine |
All Next | Launch Module |
Viridian Therapeutics Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Viridian Therapeutics' price direction in advance. Along with the technical and fundamental analysis of Viridian Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Viridian to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
Risk Adjusted Performance | (0.13) | |||
Jensen Alpha | (0.78) | |||
Total Risk Alpha | (0.82) | |||
Treynor Ratio | (0.54) |
Cycle Indicators | ||
Math Operators | ||
Math Transform | ||
Momentum Indicators | ||
Overlap Studies | ||
Pattern Recognition | ||
Price Transform | ||
Statistic Functions | ||
Volatility Indicators | ||
Volume Indicators |
Additional Information and Resources on Investing in Viridian Stock
When determining whether Viridian Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Viridian Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Viridian Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Viridian Therapeutics Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Viridian Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. To learn how to invest in Viridian Stock, please use our How to Invest in Viridian Therapeutics guide.You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Viridian Therapeutics. If investors know Viridian will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Viridian Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.49) | Revenue Per Share 0.006 | Quarterly Revenue Growth (0.27) | Return On Assets (0.29) | Return On Equity (0.47) |
The market value of Viridian Therapeutics is measured differently than its book value, which is the value of Viridian that is recorded on the company's balance sheet. Investors also form their own opinion of Viridian Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Viridian Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Viridian Therapeutics' market value can be influenced by many factors that don't directly affect Viridian Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Viridian Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Viridian Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Viridian Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.